Low Rate of Bacterial Coinfections and Antibiotic Overprescribing During COVID-19 Pandemic : A Retrospective Study from Oman
Copyright © 2023, Oman Medical Journal..
Objectives: The recommended treatment for COVID-19 includes antiviral drugs, corticosteroids, immunomodulatory drugs, low molecular weight heparin, as well as antibiotics. Although COVID-19 is a viral disease, many studies indicate that antibiotics are prescribed frequently, mainly to treat suspected bacterial coinfection. At the same time, the prevalence of bacterial coinfections during COVID-19 is rather low indicating the significant antibiotic overuse in these patients. It is well known that this can trigger antibiotic bacterial resistance, and once it emerges the reversal of resistance is a complex and long-lasting process. The aims of this study were to estimate the prevalence of bacterial coinfections during the COVID-19 and to analyze the antibiotic treatment justification during this pandemic in Oman.
Methods: This retrospective analysis was conducted using the Royal Hospital COVID-19 Registry Database. The study analyzed demographic and clinical characteristics, as well as laboratory parameters and antibiotic treatment of hospitalized patients.
Results: During the study period, 584 patients were enrolled in the analysis. Coinfection was rare as it was confirmed in 0.9% of patients. Superinfections were present in 15.2% of patients. Gram-negative bacteria were isolated in 95 (69.9%) samples, gram-positive bacteria in 25 (18.4%) samples, while Candida spp. was found in 16 (11.8%) samples. On admission, empirical antibiotic treatment was started in 543 (93.0%) patients.
Conclusions: During COVID-19, coinfections are rarely seen and the overuse of antibiotics is not justified. The incidence of superinfections is the same as in other patients in healthcare settings caused by the same resistant microorganisms, which implies the use of even more.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Oman medical journal - 38(2023), 4 vom: 08. Juli, Seite e525 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pandak, Nenad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 21.09.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.5001/omj.2023.83 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362172137 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362172137 | ||
| 003 | DE-627 | ||
| 005 | 20231226210914.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5001/omj.2023.83 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362172137 | ||
| 035 | |a (NLM)37720342 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pandak, Nenad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Low Rate of Bacterial Coinfections and Antibiotic Overprescribing During COVID-19 Pandemic |b A Retrospective Study from Oman |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.09.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023, Oman Medical Journal. | ||
| 520 | |a Objectives: The recommended treatment for COVID-19 includes antiviral drugs, corticosteroids, immunomodulatory drugs, low molecular weight heparin, as well as antibiotics. Although COVID-19 is a viral disease, many studies indicate that antibiotics are prescribed frequently, mainly to treat suspected bacterial coinfection. At the same time, the prevalence of bacterial coinfections during COVID-19 is rather low indicating the significant antibiotic overuse in these patients. It is well known that this can trigger antibiotic bacterial resistance, and once it emerges the reversal of resistance is a complex and long-lasting process. The aims of this study were to estimate the prevalence of bacterial coinfections during the COVID-19 and to analyze the antibiotic treatment justification during this pandemic in Oman | ||
| 520 | |a Methods: This retrospective analysis was conducted using the Royal Hospital COVID-19 Registry Database. The study analyzed demographic and clinical characteristics, as well as laboratory parameters and antibiotic treatment of hospitalized patients | ||
| 520 | |a Results: During the study period, 584 patients were enrolled in the analysis. Coinfection was rare as it was confirmed in 0.9% of patients. Superinfections were present in 15.2% of patients. Gram-negative bacteria were isolated in 95 (69.9%) samples, gram-positive bacteria in 25 (18.4%) samples, while Candida spp. was found in 16 (11.8%) samples. On admission, empirical antibiotic treatment was started in 543 (93.0%) patients | ||
| 520 | |a Conclusions: During COVID-19, coinfections are rarely seen and the overuse of antibiotics is not justified. The incidence of superinfections is the same as in other patients in healthcare settings caused by the same resistant microorganisms, which implies the use of even more | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antimicrobial Stewardship | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Oman | |
| 700 | 1 | |a Khamis, Faryal |e verfasserin |4 aut | |
| 700 | 1 | |a Al Balushi, Zakariya |e verfasserin |4 aut | |
| 700 | 1 | |a Chhetri, Shabnam |e verfasserin |4 aut | |
| 700 | 1 | |a Al Lawati, Adil |e verfasserin |4 aut | |
| 700 | 1 | |a AbouElhamd, Hend |e verfasserin |4 aut | |
| 700 | 1 | |a Golchinheydari, Sirous |e verfasserin |4 aut | |
| 700 | 1 | |a Sidrah, Ali Khan |e verfasserin |4 aut | |
| 700 | 1 | |a Al Jahwari, Shatha Khalid |e verfasserin |4 aut | |
| 700 | 1 | |a Al Dowaiki, Samata |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oman medical journal |d 2007 |g 38(2023), 4 vom: 08. Juli, Seite e525 |w (DE-627)NLM215843258 |x 1999-768X |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:4 |g day:08 |g month:07 |g pages:e525 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5001/omj.2023.83 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 4 |b 08 |c 07 |h e525 | ||